Testing MK-1045 for Hard-to-Treat Lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a new drug called MK-1045 for people with follicular lymphoma or diffuse large B-cell lymphoma (two types of blood cancer) that hasn't responded to at least two previous treatments. The drug is designed to target cancer cells and may help people whose cancer has come back or stopped responding to therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your lymphoma has either come back after treatment or didn't respond to at least 2 previous treatments
- You have follicular lymphoma or diffuse large B-cell lymphoma confirmed by a tissue sample
- If you have diffuse large B-cell lymphoma, you either can't have or have already tried stem cell transplant and CAR-T therapy
- You don't have lymphoma in your brain or nervous system
- If you have HIV, hepatitis B, or hepatitis C, it must be controlled or undetectable with medication
- You don't have a history of serious heart, blood vessel, or brain problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called LY4152199 for people with certain types of lymphoma (follicular or diffuse large B-cell) that came back or didn't respond to previous treatment. The goal is to see if the drug is safe and how well it works.
This early-stage trial tests a new drug called GSK5926371 in adults whose B-cell lymphoma (a blood cancer) has come back or stopped responding to previous treatments. The study aims to find out if this drug is safe and whether it can help shrink the cancer.
This trial tests a new drug called JNJ-95566692 for people with a type of lymphoma (B-cell non-Hodgkin lymphoma) that has come back or not responded to other treatments. The goal is to see if the drug can help when no other standard options are available.
This trial tests a new treatment called SynKIR-310 for people with B-cell non-Hodgkin lymphoma whose cancer has come back or not responded to at least 2 prior treatments. It may be an option if you've already had CAR T-cell therapy or cannot have it.
This trial tests a new drug called MK-1045 for people with B-cell cancers such as CLL or SLL that have come back or stopped responding to other treatments. The study aims to see if MK-1045 can help control the disease.
This trial tests a new drug called MK-1045 in patients whose acute lymphoblastic leukemia (a blood cancer) has come back or stopped responding to previous treatments. The goal is to see if this drug can help control the cancer when other options haven't worked.
Hear when a new Lymphoma, Non-Hodgkin trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.